Arrowhead Research | ARWR - Bénéfice Avant Impôts





Bénéfice Avant Impôts Changement Date
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Alnylam Pharmaceuticals USD 177.81M 43.85M 2026-06
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD -178.9M 41.34M 2026-06
Heron Therapeutics USD -2.95M 14.54M 2025-12
Incyte USD 751.51M 407.91M 2026-06
Ionis Pharmaceuticals USD -114M 21M 2026-06
Ligand Pharmaceuticals USD -24.26M 81.04M 2026-03
Merck USD -3.53B 6.95B 2026-03
Moderna USD -1.33B 535M 2026-03
Nektar Therapeutics USD -43.09M 8.39M 2026-03
Novartis USD 4.27B 430M 2026-06
Sarepta Therapeutics USD -1.75M 344.92M 2026-06
TG Therapeutics USD 10.23M 10.13M 2026-06
Ultragenyx Pharmaceutical USD -91M 93M 2026-06
Vertex Pharmaceuticals USD 1.39B 138.9M 2026-06
Xencor USD -21.92M 106.72M 2026-06